12 Best AI Drug Discovery Stocks Hedge Funds Are Loading Up On
Reuters (May 27) reported Biohub, founded by Meta CEO Mark Zuckerberg and Priscilla Chan, developed an open-source global protein-biology model using fourth-generation evolutionary scale modeling (ESM) to speed drug discovery. Biohub said it will run via Biohub.ai and partners like AWS Bio Discovery, with computing credits, and expects broader lab use. The article also lists hedge-fund “AI drug discovery” holdings, including SOPHiA Genetics’ proposed MSK precision-oncology JV and Generate Biomed
How this was made
The 30-second read
Why it matters
For SOPH, the MSK MoU could expand distribution and validation of SOPHiA’s AI analytics layer using MSK’s large tumor dataset. For GENB, the article emphasizes Phase 3 advancement and upcoming first-patient dosing windows for two programs, plus an analyst PT increase.
Market read
This is a promotional/roundup-style article, but it still contains actionable, time-stamped partnership and clinical-development milestones for SOPH and GENB.
What to watch
Key missing items include JV economics/ownership, regulatory/clinical risk for Phase 3 outcomes, and whether the cited milestones are contingent on enrollment pace or funding.
Background
The piece frames AI drug discovery as a hedge-fund favorite theme and cites Reuters’ Biohub protein-model development as industry backdrop, then lists two specific company updates.
Ticker impact
SOPHiA GENETICS signed an MoU with Memorial Sloan Kettering to form a precision oncology hub using its SOPHiA DDM platform and tumor datasets.
Near-term sentiment support, but likely limited immediate earnings impact until the JV terms and execution details are finalized.
This is a concrete partnership announcement with specific dataset/usage claims, but it is an MoU (not a binding contract) and no financial terms are provided.
Generate Biomedicines advanced GB-0895 into Phase 3 SOLAIRIA trials and expects first patient dosing for GB-4362 mid-2026 and GB-5267 in 2H 2026.
Moderate positive bias for the stock as investors price in Phase 3 progress and the mid/late-2026 trial start catalysts.
The article provides multiple time-stamped development milestones and a named analyst PT change, but it lacks trial readouts or quantified efficacy/safety results.
Market effects
Reinforces investor interest in AI-enabled drug discovery and precision oncology platforms, supporting sentiment across data/AI healthcare tech.
Primarily US-focused (MSK collaboration and US-listed biotech), with limited direct regional spillover.
Highlights global protein-model and precision-oncology collaboration trends, but no direct cross-border regulatory or market mechanism is disclosed.
Counterpoint
MoUs and pipeline timelines can fail to translate into revenue; without binding terms or clinical efficacy data, the market may quickly fade the initial enthusiasm.
Key entities
- companySOPHiA GENETICS SA
Signed an MoU with Memorial Sloan Kettering to build a precision medicine hub for next-gen precision oncology using SOPHiA DDM and MSK datasets.
- companyGenerate Biomedicines, Inc.
Reported ongoing Phase 3/Phase 1b progress and provided expected first-patient dosing timing for GB-4362 and GB-5267, alongside an analyst PT increase.
- partnerMemorial Sloan Kettering Cancer Center
Clinical diagnostics and genomic dataset provider in the proposed SOPHiA precision oncology hub.
